The páper presents the comparison of expenditure on unregistered pharmaceuticals in the second quarter of the year 2003 and 2004: high expenses on pharmaceuticals ušed for a long time and so far unregistered, newly introduced pharmaceuticals, increasing proportion of pharmaceuticals in which the registration was not renewed after their validity was finished.

        Key words: approval of unregistered pharmaceuticals by the physician reviewer - par. 16 of the law No. 48/1997 - annual increase of cost